Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4 Results for "
TAMSCs
" in MedChemExpress (MCE) Product Catalog:
Products (4)
4 Results for "TAMSCs" in MCE Product Catalog:
438
438 Publications Verification
Synonyms: Desferrioxamine B mesylate; DFOM
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
438
438 Publications Verification
Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
3
3 Cited Publications
Synonyms: Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)
Target:
Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
Synonyms: Desferrioxamine B mesylate (Standard); DFOM (Standard)
Target:
Reference Standards Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
